- Secukinumab maintained improvement in Psoriasis Activity and Severity Index (PASI) 75 (PASI75) scores in moderate-to-severe psoriasis, a 5-year phase 3 extension study showed.
Why this matters
- Secukinumab, an IL-17A monoclonal antibody, produces a complete and long-lasting response in patients with psoriasis.
- This study is the longest and largest to date to examine the long-term efficacy, safety, and tolerability of a biologic in psoriasis treatment.
- In patients receiving secukinumab, PASI responses were sustained until week 260:
- PASI75/90/100 (85.1%/ 67.2%/ 37.8%).
- PASI≤1 (46%).
- Mean PASI score (2.2) in secukinumab 300 mg stay group.
- No new safety signals were reported for secukinumab.
- Week 52 PASI75 responders from 2 pivotal trials were randomly assigned 2:1 to secukinumab (300 or 150 mg) or placebo every 4 weeks, until week 156 or relapse (as defined by >50% reduction in maximal PASI score from baseline).
- Patients who relapsed on placebo received secukinumab.
- At week 156, all patients received secukinumab (patients continued secukinumab 300 or 150 mg, or could opt to switch from 150 to 300 mg secukinumab).
- Funding: Novartis, Inc.
- Open-label study.